Myrtenal is a bicyclic monoterpene aldehyde found in aromatic plants and trace essential-oil profiles, including Bengali nagarmotha material already indexed in the AromaForge archive. The live literature is much stronger on preclinical pharmacology than on fragrance use: public sources support clear identity data, a recent review summarizing antioxidant and anti-inflammatory research, and newer animal work on renal ischemia-reperfusion injury. That evidence is still preclinical and should not be translated into medical or wellness claims for routine aroma exposure.
Chemical identity and composition
PubChem and NIST both identify myrtenal as a C10H14O bicyclic monoterpene aldehyde. NIST distinguishes the neutral structure entry from the explicitly stereospecific (-)-myrtenal page, which is useful because archive and supplier records may list either the general structure or one enantiomer. In the local oil archive, Bengali nagarmotha lists myrtenal as a minor constituent at 0.36%.
Aroma and practical use
- Use the recorded minty, piney, herbal, fresh, camphoraceous, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2025 rat study reported that myrtenal pretreatment reduced biochemical and histologic markers of renal ischemia-reperfusion injury.
The abstract reports lower BUN, creatinine, KIM-1, NGAL, IL-1beta, TNF-alpha, and MDA alongside higher SOD, CAT, and glutathione and less caspase-3 immunoreactivity after myrtenal pretreatment.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2023 review concluded that myrtenal and its derivatives have broad preclinical pharmacology including antioxidant, anti-inflammatory, antimicrobial, anticancer, anxiolytic, and neuroprotective signals.
The review frames myrtenal as a promising monoterpenoid scaffold while making clear that much of the evidence base remains experimental rather than clinical.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2026 pilot study found that myrtenal-aminoadamantane conjugates improved memory-related and oxidative-stress readouts in a rat scopolamine model.
The study supports medicinal-chemistry interest in myrtenal as a starting scaffold, but the reported benefits apply to synthesized conjugates rather than to isolated myrtenal exposure alone.
This experimental finding does not establish benefit, dose or safety in people using this blend.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedThis research pass did not identify a public, constituent-specific RIFM or CIR-style fragrance safety assessment for isolated myrtenal.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The strongest accessible benefit-oriented data are animal or derivative-scaffold studies, so consumer-facing copy should avoid disease-treatment language.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because myrtenal is an aldehydic terpene, oxidation and handling context may matter in finished materials, but this pass did not verify a public standalone dermal limit.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
gamma-TerpineneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
mechanistic · antioxidant
No source citation attached.
Read gamma-Terpinene report →How the effects were investigated
reduction of oxidative-stress burden in animal models
The reviewed literature repeatedly links myrtenal exposure with lower lipid peroxidation markers and partial restoration of endogenous antioxidant systems such as SOD, CAT, and glutathione in animal studies.
This experimental finding does not establish benefit, dose or safety in people using this blend.
downregulation of inflammatory mediators
Recent rat renal ischemia-reperfusion work reported lower IL-1beta and TNF-alpha after myrtenal pretreatment, consistent with inflammation-modulating activity in preclinical settings.
This experimental finding does not establish benefit, dose or safety in people using this blend.
supportive docking and scaffold-level cholinergic interest
Myrtenal-derived conjugates have been modeled for acetylcholinesterase affinity and blood-brain-barrier penetration, but those data belong to derivatives rather than neat myrtenal itself.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- This pass did not verify a public human clinical trial on isolated myrtenal.
- A public constituent-specific fragrance safety assessment or IFRA-style limit for isolated myrtenal was not located.
- Much of the recent neuroprotection literature concerns myrtenal derivatives rather than neat myrtenal, so structure-to-benefit extrapolation should stay conservative.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.